Clinical Trial Update: 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type [Phase 3]

View source ↗

Summary

This is a completed Phase 3 trial evaluating Xaliproden for mild-to-moderate Alzheimer's disease, with an 18-month assessment of efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Xaliproden (Xaliproden)

Snippet

Sponsor: Sanofi | Conditions: Alzheimer Disease | Phase 3 | Status: COMPLETED